These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 4431057)

  • 21. Preferential in vivo localization of 125I-labeled antibody in a carcinogen-induced syngeneic rat tumor.
    Bale WF; Contreras MA; Izzo MJ; Della Penta D; Buchsbaum DJ
    Prog Exp Tumor Res; 1974; 19():270-83. PubMed ID: 4438642
    [No Abstract]   [Full Text] [Related]  

  • 22. Two methods for detecting different aspects of the immune response to a xenograft in mice.
    Newlands ES
    Immunology; 1974 Oct; 27(4):543-52. PubMed ID: 4611905
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Allograft immunity in the mouse. 1. Quantitation and specificity of cytotoxic effector cells after in vitro sensitization.
    MacDonald HR; Phillips RA; Miller RG
    J Immunol; 1973 Aug; 111(2):565-74. PubMed ID: 4123983
    [No Abstract]   [Full Text] [Related]  

  • 24. Host immunity to a growing transplanted methylcholanthrene-induced guinea pig sarcoma.
    Cohen AM; Millar RC; Ketcham AS
    Cancer Res; 1972 Nov; 32(11):2421-6. PubMed ID: 5082590
    [No Abstract]   [Full Text] [Related]  

  • 25. In vitro measurement of cytotoxic antibodies in mouse-immune sera against mouse ascites tumor cells.
    Eng CP; Tolbert WR; Harnaha JB; Concannon JP
    Can J Microbiol; 1974 Dec; 20(12):1681-8. PubMed ID: 4479949
    [No Abstract]   [Full Text] [Related]  

  • 26. Immunity to tumours of the murine leukaemia-sarcoma virus complex.
    Owen JJ; Seeger RC
    Br J Cancer Suppl; 1973 Aug; 1():26-34. PubMed ID: 4374230
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Generation of non-complement-fixing, blocking factors by lysosomal extract treatment of cytotoxic anti-tumor antibodies.
    Dauphinee MJ; Talal N; Witz IP
    J Immunol; 1974 Sep; 113(3):948-53. PubMed ID: 4413555
    [No Abstract]   [Full Text] [Related]  

  • 28. Measurement of tumor immunity in vitro with 125 I-iododeoxyuridine-labeled target cells.
    Seeger RC; Owen JJ
    Transplantation; 1973 Apr; 15(4):404-8. PubMed ID: 4736364
    [No Abstract]   [Full Text] [Related]  

  • 29. The role of blocking antibodies in immunological enhancement.
    Takasugi M; Klein E
    Immunology; 1971 Oct; 21(4):675-84. PubMed ID: 5121758
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Correlation between changes in antitumor immune parameters and tumor growth in vivo in rats.
    Bansal SC; Sjögren HO
    Fed Proc; 1973 Feb; 32(2):165-72. PubMed ID: 4347409
    [No Abstract]   [Full Text] [Related]  

  • 31. Evaluation of cell-mediated cytotoxic reactivity against tumor associated antigens with 125I-iododeoxyuridine labeled target cells.
    Oldham RK; Herberman RB
    J Immunol; 1973 Dec; 111(6):862-71. PubMed ID: 4750872
    [No Abstract]   [Full Text] [Related]  

  • 32. 5-125I-iododeoxyuridine as prototype for radionuclide therapy with Auger emitters.
    Bloomer WD; Adelstein SJ
    Nature; 1977 Feb; 265(5595):620-1. PubMed ID: 859560
    [No Abstract]   [Full Text] [Related]  

  • 33. [Effect of the rhythm of cyclophosphamide administration on its antitumor action and on the immune response of mice with methylcholanthrene-induced sarcoma].
    Gordienko SP; Bergol'ts VM; Botsmanov KV
    Biull Eksp Biol Med; 1974 Jul; 78(7):87-90. PubMed ID: 4451721
    [No Abstract]   [Full Text] [Related]  

  • 34. Incorporation of 5-iododeoxyuridine 1311 in spontaneous C3H mouse mammary tumours.
    ROTENBERG AD; BRUCE WR; BAKER RG
    Br J Radiol; 1962 May; 35():337-42. PubMed ID: 14494361
    [No Abstract]   [Full Text] [Related]  

  • 35. Interaction of isoantibody and cytotoxic lymphocytes with allogeneic tumor cells.
    Faanes RB; Choi YS
    J Immunol; 1974 Jul; 113(1):279-88. PubMed ID: 4208919
    [No Abstract]   [Full Text] [Related]  

  • 36. Antibody production and interaction with lymphoid cells in relation to tumor immunity in the Moloney sarcoma virus system.
    Harada M; Pearson G; Redmon L; Winters E; Kasuga S
    J Immunol; 1975 Apr; 114(4):1318-22. PubMed ID: 1090675
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A lymphocytotoxicity assay not requiring the in vitro culture of target tumor cells.
    Kreider JW; Flickinger JT; Lengle N; Shoff W
    Transplantation; 1974 Sep; 18(3):223-8. PubMed ID: 4422190
    [No Abstract]   [Full Text] [Related]  

  • 38. Serum factors in mammary neoplasia: enhancement and antagonism of spleen cell activity in vitro detected by different methods of serum factor assay.
    Blair PB; Lane MA
    J Immunol; 1974 Feb; 112(2):439-53. PubMed ID: 4813898
    [No Abstract]   [Full Text] [Related]  

  • 39. Antibody-dependent, cell-mediated cytotoxicity with autochthonous lymphocytes and sera after infection with Moloney sarcoma virus.
    Lamon EW; Hale P; Whitten HD
    J Natl Cancer Inst; 1976 Feb; 56(2):349-55. PubMed ID: 1255765
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Enhanced immune reactivity to hepatoma 22a cells in MTV-infected compared with MTV-free C3H mice.
    Lavrovsky VA; Viksler VK
    Immunology; 1981 Dec; 44(4):671-6. PubMed ID: 6274791
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.